Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q9NX01
UPID:
TXN4B_HUMAN
Alternative names:
Dim1-like protein
Alternative UPACC:
Q9NX01; D3DWS6
Background:
Thioredoxin-like protein 4B, also known as Dim1-like protein, plays a crucial role in pre-mRNA splicing and is indispensable for the S/G(2) transition in cell cycle progression. Its unique function underscores its importance in cellular mechanisms and gene expression regulation.
Therapeutic significance:
Understanding the role of Thioredoxin-like protein 4B could open doors to potential therapeutic strategies. Its pivotal role in cell cycle progression and gene expression makes it a promising target for drug discovery efforts aimed at treating diseases with underlying genetic and cellular dysregulations.